Risk Factors Update Summary
- The company effected a reduction in authorized common stock on a 1-for-10 basis.
- The company had until November 30, 2023, to regain compliance with the minimum bid price.
- The company may not continue to meet Nasdaq listing requirements, which could lead to delisting.
- Failure to regain compliance with Nasdaq listing rules could severely limit stock liquidity.
- The DNase platform is focused on developing treatments for pancreatic cancer, CRC, and other gastrointestinal cancers.
- The company aims to advance the systemic DNase program with milestones targeted for 2024-2025.
- The company had an accumulated deficit of approximately $193 million as of December 31, 2023.
- The company had cash of approximately $139 million as of December 31, 2023, requiring additional funding.
- The company's primary focus is now on advancing the DNase oncology platform technology.
- The company employs four full-time employees as of December 31, 2023, with plans to expand.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1534525&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.